Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Cemiplimab

Subacute cutaneous lupus erythematosus and immune-related hepatitis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fietz S, et al. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report. Frontiers in Immunology 14: Jan 2023. Available from: URL: https://dx.doi.org/10.3389/fimmu.2023.1324231 Fietz S, et al. Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report. Frontiers in Immunology 14: Jan 2023. Available from: URL: https://dx.doi.org/10.3389/fimmu.2023.1324231
Metadaten
Titel
Cemiplimab
Subacute cutaneous lupus erythematosus and immune-related hepatitis
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52578-3

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Gabapentin

Case report

Antibacterials